

WADA Publishes Revised International Standard for Therapeutic Use Exemptions

Montreal, November 3, 2009 – Following approval by its Executive Committee, the World Anti-Doping Agency (WADA) has now published the revised International Standard for Therapeutic Use Exemptions (ISTUE). This Standard will take effect on January 1, 2010.

The ISTUE was revised as a result of the adoption of the 2010 Prohibited List. The ISTUE had to be amended to accommodate some of the changes to the List to be implemented on January 1, 2010, in particular the removal of inhaled salbutamol from the List. This resulted in the deletion of Annex 1 and of the special provision in relation to Beta-2 agonists of the ISTUE.

Under the 2010 List, salbutamol, salmeterol, platelet-derived preparations, and glucocorticosteroids administered by some routes will require a Declaration of Use. In order to avoid frequent changes to the ISTUE, the name of the substances that require a Declaration of Use is no longer included in the ISTUE, but rather is clearly indicated in the List.

Furthermore, in order to simplify the ISTUE, a number of provisions were rewritten or reordered, maintaining however all the key principles of the Standard.

To consult the revised ISTUE, click [here](#).

WADA Launches New Web Site

Montreal, November 3, 2009 – The World Anti-Doping Agency (WADA) launched its new Web site today, coinciding with its tenth anniversary on November 10, 2009.

The new Web site features improved navigation and reorganized content to better fulfill its users' needs.

An entirely new section, called "Anti-Doping Community", was created to cater to the particular needs of WADA's key stakeholders, including athletes, the sport movement and governments. In this section, each of these groups will find information specifically related to their anti-doping responsibilities and areas of interest.

For any question or feedback, please contact info@wada-ama.org.

Discover WADA's new Web site at www.wada-ama.org.